A broad-host-range inhalable phage cocktail for treatment of multidrug-resistant Pseudomonas aeruginosa pulmonary infections

Introduction

The growing threat of multidrug-resistant (MDR) Pseudomonas aeruginosa (P. aeruginosa) has created an urgent need for novel therapeutic strategies to combat refractory lung infections. The limited efficacy of traditional antibiotics against this pathogen highlights the necessity of developing alternative treatments. Our study aims to develop a broad-spectrum bacteriophage cocktail suitable for nebulization and to evaluate its antibacterial efficacy and safety in respiratory infections caused by MDR P. aeruginosa.